Active, not recruiting
Not applicable
A Clinical Trial to Evaluate the Effects of Super Lungs Liquid Drops on Respiratory Comfort, Airway Soothing, and Overall Well-Being
Condition(s) studied
CoughingThroat Irritation
Investigational drug(s) / intervention(s)
Super Lungs Liquid Drops
Super Lungs Liquid Drops: All 35 participants receive Super Lungs Liquid Drops at 2 mL daily (two full droppers of 1 mL each), administered once daily with the first meal of the day, for 12 weeks.
Study summary
This is a single-group, open-label, fully decentralized (virtual) clinical trial evaluating the effects of Super Lungs Liquid Drops on respiratory comfort, airway soothing, and overall well-being in generally healthy adults aged 18-65 who experience bothersome respiratory symptoms. All 35 enrolled participants will receive the active study product and self-administer 2 mL of the drops daily (two full droppers of 1 mL each, once daily with the first meal of the day) for 12 weeks.
Eligibility
Inclusion Criteria:
* Adults aged 18-65 years.
* Over the past two months, has experienced bothersome coughing on a weekly basis.
* Anyone who has experienced issues with at least two of the following over the past four weeks: chest tightness or congestion; persistent throat irritation or itchiness; excess mucus or phlegm buildup.
* Generally healthy, without any uncontrolled chronic disease.
* Willing to maintain their current diet, sleep pattern, and activity levels for the duration of the trial.
* Resides in the United States.
* Has access to the internet and a device (smartphone, tablet, or computer) capable of completing online questionnaires.
* Willing to follow the study protocol and complete all required assessments.
Exclusion Criteria:
* Anyone with a known allergy or sensitivity to any of the study product ingredients.
* Anyone with a known allergy to plants in the Asteraceae/Compositae family.
* Women who are pregnant, breastfeeding, or planning to become pregnant during the study period.
* Anyone currently taking immunosuppressant medications (e.g., cyclosporine, methotrexate, biologics such as adalimumab or infliximab).
* Anyone with a diagnosed autoimmune disorder (e.g., lupus, rheumatoid arthritis, multiple sclerosis).
* Anyone with uncontrolled hypertension or currently taking antihypertensive medications, diuretics, or corticosteroids.
* Anyone currently taking anticoagulant or antiplatelet medications (e.g., warfarin, heparin, clopidogrel).
* Anyone with a chronic health condition that could impact their participation in this study, such as cancer, mental health disorders, a history of serious illness in the last three months, a history of substance abuse, or planned surgery during the study period.
* Anyone with a history of alcohol use disorder or currently in alcohol recovery.
* Anyone currently participating in another research study or who plans to participate in another study during the study period. (
Primary outcome measure(s)
- Respiratory comfort — Baseline, Week 2, Week 4, Week 8, and Week 12
Change in self-reported respiratory comfort assessed by questionnaires.
- Normal airway function — Baseline, Week 2, Week 4, Week 8, and Week 12
Change in self-reported normal airway function assessed by questionnaires.
Trial sites (1)
| Facility | City | Region | Status |
|---|
| Citruslabs |
Las Vegas |
Nevada |
|
More SuperBonsai Inc. trials in the USA